| Assessment Status | Assessment Process Complete |
| HTA ID | 20008 |
| Drug | Ruxolitinib |
| Brand | Jakavi® |
| Indication | For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. |
| Assessment Process | |
| Rapid review commissioned | 15/04/2015 |
| Rapid review completed | 28/05/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 13/04/2016 |
| NCPE assessment completed | 16/08/2016 |
| NCPE assessment outcome | Reimbursement Not Recommended |
Resubmission of HTA
| Assessment Process | Assessment Process Complete |
| Resubmission of HTA commissioned by the HSE | 04/03/2020 |
| Pre-submission consultation with Applicant | 09/03/2020 |
| Full submission received from Applicant | 16/09/2020 |
| Preliminary review sent to Applicant | 01/04/2021 |
| NCPE assessment re-commenced | 04/05/2021 |
| Follow-up preliminary review sent to Applicant | 19/05/2021 |
| NCPE assessment re-commenced | 26/05/2021 |
| Factual accuracy sent to Applicant | 28/06/2021 |
| NCPE assessment re-commenced | 09/07/2021 |
| NCPE assessment completed | 21/07/2021 |
| NCPE assessment outcome | The NCPE recommends that ruxolitinib (Jakavi®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.